Lonza expands cell and gene therapy plant it is building in Texas

By Gareth Macdonald contact

- Last updated on GMT

Lonza expands cell and gene therapy plant it is building in Texas

Related tags: Gene

The cell and gene therapy plant Lonza is building in Pearland, Texas will be bigger than originally planned to according to the city’s economic development corporation.

When Lonza started work on the facility this year​ its intention was to create a 100,000 square foot plant at which it will produce commercial quantities of viral gene and cell therapies.

This week the Swiss firm committed to add an additional 150,000 square feet of manufacturing space at the site according to an announcement​ by the Pearland Economic Development Corporation. The facility is scheduled to open at the end of 2017.

The decision follows a few months​ after Lonza was contracted by Bluebird Bio to manufacture its Lenti-D and LentiGlobin products at the facility.

At the time, company spokesman Dirk Oehlers told us the deal was a further indication of growing demand for the type of specialist contract manufacturing skills needed to make cell and gene therapies.

 Synthetic AAVs

News of the plant expansion also follows just a few weeks after Lonza licensed rights to synthetic adeno-associated viral (AAV) vectors and associated production technologies from US hearing research centre, Massachusetts Eye and Ear.

Luk Vandenberghe, from Massachusetts Eye and Ear, told us the tech – which Lonza will use at Pearland - is used to “optimize AAVs for therapeutic gene transfer applications on clinically relevant parameters including host immunity, production yields, tissue targeting and specificity​.”

The benefit of this approach is that it enables rationally informed design of therapeutic gene transfer vectors to address aspects important to safety and efficacy​. “

The lead vector Anc80L65 – licensed by Lonza – was “generated using this approach and subsequently extensively characterized” Vandenberghe continued, adding that it “demonstrates benefits for applications in the muscle, retina, and​ live​”

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars